Posted on February 23, 2017
Dr. Patrick Boland is a medical oncologist at Roswell Park Cancer Institute in Buffalo, New York, where he works as part of the gastrointestinal oncology team treating patients with lower gastrointestinal cancers. His clinical interests include colorectal cancer and the development of new cancer therapies.
Immunotherapy in Colorectal Cancer
Immunotherapy 2.0 was recently named by the American Society of Clinical Oncology (ASCO) as the Advance of the Year. The 2.0 moniker is meant to symbolize expansion of these treatments to more patients, while simultaneously improving our ability to identify which patients will benefit from which treatment. Above all, this underscores the excitement we are all are experiencing in relation to immunotherapy. Read more
Posted on February 13, 2017
It’s that time of year again, after the big major holidays have passed and before the beautiful, renewing Spring weather returns, that we find pink and red hearts everywhere. Yeah, you guessed it, Valentine’s Day.
But does that mean romance is in the air if you’re a cancer survivor?
You betcha! Read more
Posted on February 8, 2017
In the spirit of Valentine’s Day, we thought we’d cover the tough topic of sex after cancer.
Survivors may experience a range of intimacy issues depending on the type of treatment. For example, men may experience periods of low testosterone after chemotherapy or erection problems and a reduced sperm count after radiation to the pelvic area, while some women may experience sudden menopause after chemotherapy or have their ovaries removed during surgery to remove their rectum. Not to mention personal concerns about your ostomy during sex. Read more
Posted on February 7, 2017
The American Society of Clinical Oncology, more commonly known as ASCO, has flipped the traditional clinical trial model on its head, seeking to give greater access to new treatments to patients as well as understand the complex genetics involved. The clinical trial is called TAPUR, and the key difference is identifying a treatment by a patient’s tumor type, regardless of the tumor’s location. Read more
Posted on December 1, 2016
Our Conversations Webinar Series is an opportunity to link national experts in colorectal cancer and other related fields to you, right in the comfort of your own home. The programs are designed to empower you to play a leading role in your healthcare management.
Last month, our webinar focused on 5-FU, the most common colorectal cancer treatment, where we explored the history and benefits, as well as the causes and treatment of toxicities that arise in many patients. Participants listened in and asked the following questions. Read more